Growth Metrics

Merck (MRK) Capital Expenditures (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.07%
Dec 31, 2025 4.66%
Sep 30, 2025 29.19%
Jun 30, 2025 -42.47%
Mar 31, 2025 41.73%
Dec 31, 2024 19.67%
Sep 30, 2024 -1.01%
Jun 30, 2024 -8.13%
Mar 31, 2024 -12.94%
Dec 31, 2023 9.65%
Sep 30, 2023 -6.53%
Jun 30, 2023 -4.17%
Mar 31, 2023 -12.36%
Dec 31, 2022 2.04%
Sep 30, 2022 -0.27%
Jun 30, 2022 14.74%
Mar 31, 2022 -18.54%
Dec 31, 2021 3.07%
Sep 30, 2021 18.86%
Jun 30, 2021 -8.87%
Mar 31, 2021 -24.39%
Dec 31, 2020 373.84%
Sep 30, 2020 -46.74%
Jun 30, 2020 -42.49%
Mar 31, 2020 -4.55%
Dec 31, 2019 7.72%
Sep 30, 2019 22.63%
Jun 30, 2019 31.43%
Mar 31, 2019 -35.95%
Dec 31, 2018 42.27%
Sep 30, 2018 12.01%
Jun 30, 2018 29.56%
Mar 31, 2018 -37.06%
Dec 31, 2017 62.13%
Sep 30, 2017 12.21%
Jun 30, 2017 15.93%
Mar 31, 2017 -38.48%
Dec 31, 2016 34.72%
Sep 30, 2016 9.07%
Jun 30, 2016 34.41%
Mar 31, 2016 -43.41%
Dec 31, 2015 56.01%
Sep 30, 2015 16.61%
Jun 30, 2015 33.50%
Mar 31, 2015 -58.57%
Dec 31, 2014 53.13%
Sep 30, 2014 5.96%
Jun 30, 2014 47.32%
Mar 31, 2014 -52.21%
Dec 31, 2013 20.85%
Sep 30, 2013 -14.04%
Jun 30, 2013 17.66%
Mar 31, 2013 -54.88%
Dec 31, 2012 87.92%
Sep 30, 2012 -3.94%
Jun 30, 2012 30.21%
Mar 31, 2012 -45.11%
Dec 31, 2011 39.91%
Sep 30, 2011 18.08%
Jun 30, 2011 12.65%
Mar 31, 2011 -50.91%
Dec 31, 2010 95.27%
Sep 30, 2010 0.30%
Jun 30, 2010 -1.75%
Mar 31, 2010 -38.46%
Dec 31, 2009 83.78%
Sep 30, 2009 -16.95%
Jun 30, 2009 55.34%